News
Entospletinib falls short in relapsed/refractory DLBCL
The oral, selective inhibitor of spleen tyrosine kinase had a high rate of adverse events and treatment interruption in the phase 2 study.
News
Frontline rituximab shows long-term success in indolent lymphoma
A study with 10-year follow-up data suggests that chemotherapy can be delayed in symptomatic indolent lymphoma patients.
News
AITL responds to 5-azacytidine in small series
The small study showed high response and no significant safety concerns.
Article
Brentuximab vendotin plus CHP meets PFS endpoint in ECHELON-2
Takeda Pharmaceuticals and Seattle Genetics announced phase 3 trial results in frontline treatment of peripheral T-cell lyphoma (PTCL).
News
New mantle cell trials launching
At least four new mantle cell lymphoma trials were registered in Clinicaltrials.gov in August 2018.
News
New BTK inhibitor under review in China
Zanubrutinib is being reviewed for treatment of relapsed/refractory mantle cell lymphoma.
News
Blood disorders researcher is finalist for Trailblazer Prize
Dr. Daniel Bauer of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, was recognized for his research on sickle cell disease and...
News
PET/CT accurately predicts MCL stage
The promising results suggest bone marrow involvement could be assessed without a biopsy.
News
Ibrutinib stacks up well on safety in pooled analysis
The study looked at ibrutinib safety for CLL/SLL and MCL across four studies.
News
FDA issues guidance for hemophilia gene therapy development
The agency issued three disease-specific gene therapy guidances, including for retinal disorders and rare diseases.
News
Pfizer launches phase 3 gene therapy study in hemophilia B
Fidanacogene elaparvovec is an investigational gene therapy aimed at allowing hemophilia B patients to live free of routine infusions.
News
Lab results may help predict complications in ALL treatment
Researchers identified factors that predict which pediatric ALL patients were likely to have a longer hospital stay after induction chemotherapy...
News
Promising phase 3 results for ixazomib in multiple myeloma
The drug met the primary endpoint in a phase 3 study of maintenance therapy after stem cell transplant.
News
European Medicines Agency recommends CAR T-cell approvals
The therapies must be approved by the European Commission before they can be marketed to patients.